Once known mainly for their role in weight management, GLP-1 receptor agonists, like semaglutide and tirzepatide, are now ...

CONSHOHOCKEN, PA, USA I July 30, 2025 I Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal”) today announced that it has entered into an exclusive ...

A recent study shows the use of GLP-1 drugs can increase the risk for optic nerve damage in the first year of treatment, ...

The idea is that SYH2086 can be paired with Rezdiffra, a selective thyroid hormone receptor agonist that became the first FDA-approved drug for metabolic dysfunction-associated steatohepatitis (MASH) ...

The American Academy of Pediatrics lit the fuse in 2023. Their recommendation to use GLP-1 weight-loss drugs in children and adolescents wasn’t just a nod to pharmaceutical innovation — it was a ...

U.S. drugmaker Madrigal Pharmaceuticals has struck a licensing deal with CSPC Pharmaceutical Group that could be worth more than $2 billion for the Chinese company if it results in a new drug for a ...

Orfoglipron was associated with improved glycemic control and weight reduction among patients with early-stage type 2 diabetes.

Though nerves abound for funders and founders in the industry, money continues to flow into startups, sometimes in ...

Oral, non-opioid drug candidate advancing through Phase 1 and nearing completion of the single ascending dose (SAD) portion ...

A diabetes medication may offer relief for people suffering from chronic migraines. In a new study, researchers found that ...

Discover the rise of "Ozempic face" linked to weight loss drugs like semaglutide, its cosmetic effects, and treatments like ...

Britons are “ cheating the system ” to use weight-loss jabs before their holidays, Wes Streeting has claimed. The Health Secretary claimed people are pretending to be overweight so that they could get ...